<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398550</url>
  </required_header>
  <id_info>
    <org_study_id>2020P000298</org_study_id>
    <nct_id>NCT04398550</nct_id>
  </id_info>
  <brief_title>SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis</brief_title>
  <official_title>Specific Carbohydrate Diet vs. Mediterranean Diet Therapy in Ulcerative Colitis - A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although patients and physicians have shown tremendous interest in the effect of diet on
      ulcerative colitis, there is a lack of significant evidence for providers to make practical
      recommendations with. In this study, the investigators hope to find out if dietary therapy by
      either the Specific Carbohydrate Diet (SCD) or the Mediterranean diet will help improve
      ulcerative colitis symptoms for patients with mild to moderately active disease. In addition,
      the investigators will compare disease activity and changes in the intestinal bacterial
      composition in the colon that occur with the Mediterranean or the SCD diet in active
      ulcerative colitis.

      This study is proposed as a single-site randomized trial consisting of 10 study visits to
      Massachusetts General Hospital (MGH) over 12 weeks. Participants in this study will be
      randomly assigned to the SCD or Mediterranean diet. The investigators ask that participants
      exclusively consume their assigned diet for 6 weeks, with all meals and snacks prepared by
      the metabolic kitchen within MGH. Participants will need to pick up food from MGH every 5-7
      days, and will meet with a study dietitian before they begin and weekly during the diet
      therapy.

      There will be a screening visit to determine eligibility for the study, as well as study
      visits at weeks 0, 1, 2, 4, 6, and a 10 week follow-up at MGH, in which participants will
      fill out questionnaires. Participants will need to provide stool samples at screening, week
      6, and week 10. In addition, blood will be drawn at week 0 and week 6, and if participants
      are getting a clinically-indicated colonoscopy at the time of screening, up to eight research
      biopsies may be collected during the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The investigators, subjects, and remaining study staff will not be intentionally unblinded. Due to the nature of the study, subjects, study staff, and investigators interacting with the subjects will likely be able to figure out what diet the subject is assigned to, however, the exact diet will not be explicitly revealed to them.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Partial Mayo Clinic Score</measure>
    <time_frame>Week 6</time_frame>
    <description>The partial Mayo clinic score measures disease activity, on a scale of 0 to 9. The higher scores indicate more severe disease activity (the worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial Mayo Clinic Score</measure>
    <time_frame>Week 1, Week 2, Week 4, Week 10 follow-up</time_frame>
    <description>The partial Mayo clinic score measures disease activity, on a scale of 0 to 9. The higher scores indicate more severe disease activity (the worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire (IBDQ10)</measure>
    <time_frame>Week 1, Week 2, Week 4, Week 6, and Week 10 follow-up</time_frame>
    <description>The IBDQ10 measures quality of life, on a scale of 10 to 70. The higher scores indicate a better outcome (better quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (12) Health Survey (SF-12)</measure>
    <time_frame>Week 1, Week 2, Week 4, Week 6, and Week 10 follow-up</time_frame>
    <description>The SF-12 measures health-related quality of life, split into physical and mental health scores on a scale of 0 to 100. The higher scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simple Clinical Colitis Activity Index (SCCAI)</measure>
    <time_frame>Week 1, Week 2, Week 4, Week 6, and Week 10 follow-up</time_frame>
    <description>The SCCAI measures disease activity, on a scale of 0 to 21. The higher scores indicate a worse outcome (more severe disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool microbiome</measure>
    <time_frame>Week 6 and Week 10 follow-up</time_frame>
    <description>Stool samples will be taken at screening/baseline and week 6 and 10 to assess change in fecal microbiome pattern, measured using R2Aspread plating, QiagenAllPrep RNA/DNA Mini kit, and whole genome shotgun sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal calprotectin</measure>
    <time_frame>Week 6 and Week 10 follow-up</time_frame>
    <description>Stool samples will be taken at screening/baseline and week 6 and 10 to assess change in fecal calprotectin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Week 6</time_frame>
    <description>Blood will be drawn at baseline and week 6 to assess change in C-reactive protein levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Specific Carbohydrate Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exclusive consumption of the specific carbohydrate diet for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mediterranean Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exclusive consumption of the Mediterranean diet for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specific Carbohydrate Diet</intervention_name>
    <description>Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.</description>
    <arm_group_label>Specific Carbohydrate Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mediterranean Diet</intervention_name>
    <description>Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.</description>
    <arm_group_label>Mediterranean Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of active ulcerative colitis for at least 3 months before screening

          -  Ulcerative colitis confirmed by colonoscopy or flexible sigmoidoscopy within 2 years
             of screening

          -  Mild to moderate ulcerative colitis at the time of screening (2 &lt; Mayo score &lt; 12)

          -  1 ≤ Endoscopy subscore ≤ 2, or fecal calprotectin &gt; 150 mcg/g within 2 weeks of
             screening

          -  Patients on 5-aminosalicylates (e.g. mesalamine, etc.) must be on a stable dose for ≥
             4 weeks prior to screening

          -  Patients on treatment with immunosuppressive (azathioprine/6-mercaptopurine and
             methotrexate) or biologic medications (infliximab, adalimumab, and golimumab) must be
             on stable dose for 8 weeks prior to baseline

          -  At the time of baseline, patients may be on no more than 20 mg of prednisone and 9 mg
             of budesonide MMX

        Exclusion Criteria:

          -  Patients with Crohn's disease or indeterminate colitis

          -  History of colectomy

          -  Presence of ileal pouch or ostomy

          -  History of colonic dysplasia

          -  Evidence of active bacterial or viral gastroenteritis as indicated by positive stool
             studies for ova &amp; parasites, clostridium difficile, and stool culture

          -  Severe to fulminant colitis

          -  Recent hospitalizations (within 2 weeks of screening) for ulcerative colitis requiring
             IV steroids

          -  Recent systemic antibiotics use (within 2 weeks of screening)

          -  Presence of the following labs indicative of severe colitis: a. Hemoglobin &lt; 8.0 g/dl
             b. Albumin &lt; 3.0 g/dl

          -  Use of Total Parenteral Nutrition (TPN)

          -  Active use of anti-diarrheal medications

          -  Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamed Khalili, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hamed Khalili, MD, MPH</last_name>
    <phone>978-882-6709</phone>
    <email>hkhalili@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Glasser</last_name>
    <phone>617-643-9374</phone>
    <email>rglasser@mgh.harvard.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology. 2014 May;146(6):1564-72. doi: 10.1053/j.gastro.2014.01.058. Epub 2014 Feb 4. Review.</citation>
    <PMID>24503132</PMID>
  </reference>
  <reference>
    <citation>Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut. 1994 May;35(5):665-8.</citation>
    <PMID>8200562</PMID>
  </reference>
  <reference>
    <citation>Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):279-84.</citation>
    <PMID>14973103</PMID>
  </reference>
  <reference>
    <citation>Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, Bonnet R, Darfeuille-Michaud A, Barnich N. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014 Jan;63(1):116-24. doi: 10.1136/gutjnl-2012-304119. Epub 2013 Apr 18.</citation>
    <PMID>23598352</PMID>
  </reference>
  <reference>
    <citation>Stenman LK, Holma R, Eggert A, Korpela R. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol. 2013 Feb 1;304(3):G227-34. doi: 10.1152/ajpgi.00267.2012. Epub 2012 Nov 29.</citation>
    <PMID>23203158</PMID>
  </reference>
  <reference>
    <citation>Lee D, Albenberg L, Compher C, Baldassano R, Piccoli D, Lewis JD, Wu GD. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015 May;148(6):1087-106. doi: 10.1053/j.gastro.2015.01.007. Epub 2015 Jan 15. Review.</citation>
    <PMID>25597840</PMID>
  </reference>
  <reference>
    <citation>Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004 Oct;53(10):1479-84.</citation>
    <PMID>15361498</PMID>
  </reference>
  <reference>
    <citation>Magee EA, Edmond LM, Tasker SM, Kong SC, Curno R, Cummings JH. Associations between diet and disease activity in ulcerative colitis patients using a novel method of data analysis. Nutr J. 2005 Feb 10;4:7.</citation>
    <PMID>15705205</PMID>
  </reference>
  <reference>
    <citation>Degagné E, Pandurangan A, Bandhuvula P, Kumar A, Eltanawy A, Zhang M, Yoshinaga Y, Nefedov M, de Jong PJ, Fong LG, Young SG, Bittman R, Ahmedi Y, Saba JD. Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest. 2014 Dec;124(12):5368-84. doi: 10.1172/JCI74188. Epub 2014 Oct 27.</citation>
    <PMID>25347472</PMID>
  </reference>
  <reference>
    <citation>Jantchou P, Morois S, Clavel-Chapelon F, Boutron-Ruault MC, Carbonnel F. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. Am J Gastroenterol. 2010 Oct;105(10):2195-201. doi: 10.1038/ajg.2010.192. Epub 2010 May 11.</citation>
    <PMID>20461067</PMID>
  </reference>
  <reference>
    <citation>Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, Takabe K, Kordula T, Milstien S, Spiegel S. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013 Jan 14;23(1):107-20. doi: 10.1016/j.ccr.2012.11.013. Epub 2012 Dec 27.</citation>
    <PMID>23273921</PMID>
  </reference>
  <reference>
    <citation>Ijssennagger N, Belzer C, Hooiveld GJ, Dekker J, van Mil SW, Müller M, Kleerebezem M, van der Meer R. Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):10038-43. doi: 10.1073/pnas.1507645112. Epub 2015 Jul 27.</citation>
    <PMID>26216954</PMID>
  </reference>
  <reference>
    <citation>Ĳssennagger N, Derrien M, van Doorn GM, Rijnierse A, van den Bogert B, Müller M, Dekker J, Kleerebezem M, van der Meer R. Dietary heme alters microbiota and mucosa of mouse colon without functional changes in host-microbe cross-talk. PLoS One. 2012;7(12):e49868. doi: 10.1371/journal.pone.0049868. Epub 2012 Dec 11.</citation>
    <PMID>23239972</PMID>
  </reference>
  <reference>
    <citation>Zimmermann MB, Chassard C, Rohner F, N'goran EK, Nindjin C, Dostal A, Utzinger J, Ghattas H, Lacroix C, Hurrell RF. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. Am J Clin Nutr. 2010 Dec;92(6):1406-15. doi: 10.3945/ajcn.110.004564. Epub 2010 Oct 20.</citation>
    <PMID>20962160</PMID>
  </reference>
  <reference>
    <citation>Werner T, Wagner SJ, Martínez I, Walter J, Chang JS, Clavel T, Kisling S, Schuemann K, Haller D. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut. 2011 Mar;60(3):325-33. doi: 10.1136/gut.2010.216929. Epub 2010 Nov 12.</citation>
    <PMID>21076126</PMID>
  </reference>
  <reference>
    <citation>Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, Muller DN, Hafler DA. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013 Apr 25;496(7446):518-22. doi: 10.1038/nature11868. Epub 2013 Mar 6.</citation>
    <PMID>23467095</PMID>
  </reference>
  <reference>
    <citation>Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, Regev A, Kuchroo VK. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature. 2013 Apr 25;496(7446):513-7. doi: 10.1038/nature11984. Epub 2013 Mar 6.</citation>
    <PMID>23467085</PMID>
  </reference>
  <reference>
    <citation>Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, Gennert D, Satija R, Shakya A, Lu DY, Trombetta JJ, Pillai MR, Ratcliffe PJ, Coleman ML, Bix M, Tantin D, Park H, Kuchroo VK, Regev A. Dynamic regulatory network controlling TH17 cell differentiation. Nature. 2013 Apr 25;496(7446):461-8. doi: 10.1038/nature11981. Epub 2013 Mar 6.</citation>
    <PMID>23467089</PMID>
  </reference>
  <reference>
    <citation>HAAS SV, HAAS MP. The treatment of celiac disease with the specific carbohydrate diet; report on 191 additional cases. Am J Gastroenterol. 1955 Apr;23(4):344-60.</citation>
    <PMID>14361377</PMID>
  </reference>
  <reference>
    <citation>Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015 Jan;64(1):93-100. doi: 10.1136/gutjnl-2014-307264. Epub 2014 Jul 12.</citation>
    <PMID>25016597</PMID>
  </reference>
  <reference>
    <citation>Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut. 2006 Mar;55(3):348-55. Epub 2005 Sep 14.</citation>
    <PMID>16162680</PMID>
  </reference>
  <reference>
    <citation>Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Muir JG, Gibson PR. Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn's Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. Clin Transl Gastroenterol. 2016 Apr 14;7:e164. doi: 10.1038/ctg.2016.22.</citation>
    <PMID>27077959</PMID>
  </reference>
  <reference>
    <citation>De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14691-6. doi: 10.1073/pnas.1005963107. Epub 2010 Aug 2.</citation>
    <PMID>20679230</PMID>
  </reference>
  <reference>
    <citation>Obih C, Wahbeh G, Lee D, Braly K, Giefer M, Shaffer ML, Nielson H, Suskind DL. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition. 2016 Apr;32(4):418-25. doi: 10.1016/j.nut.2015.08.025. Epub 2015 Nov 30.</citation>
    <PMID>26655069</PMID>
  </reference>
  <reference>
    <citation>Suskind DL, Cohen SA, Brittnacher MJ, Wahbeh G, Lee D, Shaffer ML, Braly K, Hayden HS, Klein J, Gold B, Giefer M, Stallworth A, Miller SI. Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease. J Clin Gastroenterol. 2018 Feb;52(2):155-163. doi: 10.1097/MCG.0000000000000772.</citation>
    <PMID>28030510</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Hamed Khalili</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine at Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only de-identified information may be shared with other collaborators and entities involved in generating data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

